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SUMMARY 
What is known? 
• Intraventricular haemorrhages (IVH) caused by rapid changes in blood 
pressure in neonates lead to adverse effects such as poor long-term 
neurodevelopment and increased mortality.  
• Inotropes, commonly dopamine, are used in neonatal intensive care units 
(NICU) to treat hypotension by increasing peripheral vascular resistance.  
• Majority of studies that observed dopamine instability have utilised protocols 
with high temperature (>50 °C).  
 
What this study adds? 
• Laboratory studies on dopamine instability under simulated NICU settings 
show rapid degradation within the first hour of the infusion, followed by 
gradual degradation over 24 hours.  
• This coincides with a rapid fluctuation in mean arterial pressure (MAP) 
observed following infusion changeover of dopamine.  
• Changing our standard operating procedure (SOP) so that dopamine 
infusions were administered 30 minutes after preparation and for a duration 
of 12 hours removed rapid fluctuations observed in the MAP during infusion 
changeover.  
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ABSTRACT 
OBJECTIVE To evaluate whether changing dopamine infusions every 12 hours and 
preparing these infusions 30 minutes before administration reduces blood pressure 
fluctuations in pre-term and term neonates.  
DESIGN This was a retrospective study using data from live patients on the neonatal 
unit and prospective study exploring stability of infusions in a laboratory based 
neonatal ward simulation. 
SETTING Single centre study in a tertiary neonatal surgical unit in a university 
teaching hospital.  
PATIENTS Neonates who received more than one subsequent dopamine infusion and 
had invasive arterial blood pressure monitoring, during their admission in the neonatal 
unit, were included.  
INTERVENTIONS As part of the Quality Improvement project the SOP was changed, 
and dopamine infusions were prepared by nursing staff and left to rest for 30 minutes 
before administering to the neonate. Additionally, infusions were replaced every 12 
hours. 
MAIN OUTCOME MEASURES The percentage change in mean arterial pressure 
(MAP) and the percentage loss in the drug concentration during infusion during 
changeover.  
RESULTS Our findings indicate that up to 15 % of the initial dopamine concentration 
is lost after 24 hours. This results in a sharp variation in the dopamine concentration 
during infusion changeover that correlates with observed rapid fluctuations in MAP. In 
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changing the SOP, no signficant difference in the concentration of dopamine and MAP 
were observed over 12-hours. 
CONCLUSIONS Delaying administration of dopamine infusions by 30 minutes after 
preparation combined with changing infusions 12 hourly has reduced MAP 
fluctuations. Therefore, the risks associated with MAP fluctuations, including 
intraventricular haemorrhages, are reduced.  
  
 
Introduction 
Neonatal hypotension is a common condition with one third to a half of neonates being 
hypotensive within 24 hours of admission to neonatal intensive care units (NICUs) 1. 
This hypotension can be transient or persisting depending on its cause 2-4. Neonatal 
hypotension is initially treated with volume support followed by inotrope therapy 
(dopamine or dobutamine) if blood pressure (BP) has not improved. The main goal of 
initiating inotrope therapy in a hypotensive neonate is to increase cardiac output and 
raise BP thereby maintaining adequate organ and tissue perfusion 5 6. Although 
inotrope therapy is widely used in neonatal hypotension, its efficacy in this patient 
population is often debated 7-10. At present, there is a lack of neonatal specific 
formulations and doses are prepared from adult vials. There are also observations of 
the fluctuations in BP following inotropic infusion changeover 11-14. It has been 
proposed that these fluctuations in BP can lead to poor organ perfusion, 
intraventricular haemorrhage (IVH), periventricular leukomalacia (PVL), retinopathy of 
prematurity and mortality 15. Additionally, IVH have been associated with poor 
neurological, motor and cognitive outcomes at both 1 and 2-3 years of age 16. It is 
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currently unclear whether the fluctuations arise as a result of therapy or hypotension 2 
4 7 17 but given the risks associated, it is crucial to minimise the fluctuations where 
possible. 
 
The infusion changeover technique 14 18, knowledge and training of the nursing staff, 
19 and the stability of dopamine itself have been investigated as possible reasons for 
these BP fluctuations following infusion changeover. Little alteration in the frequency 
of rapid fluctuations in BP were observed when changeover technique and training of 
nursing staff were investigated as a cause. Stability studies have questioned 
dopamine’s stability when exposed to light, plastic, infusion vehicles and other drugs 
20-27. Many of the stability studies conducted on dopamine were undertaken at room 
temperature and concluded dopamine to be stable. Stability was assumed at all 
temperatures, which led to dopamine being used in neonatal clinical practice. The 
doses used in these stability studies were often unrepresentative of clinical dosing 
regimens, therefore their conclusions cannot be applied to the neonatal population. 
The lack of data representative of the neonatal environment led to the study which 
assessed the role of light and infusion vehicles on dopamine’s stability at 35 °C, where 
a loss in stability was observed 20.  
 
In this retrospective and prospective study, we evaluated how the MAP varied during 
infusion changeover following implementation of a new standard operating procedure 
(SOP) for delivery of dopamine as part of the unit´s quality improvement project. This 
SOP was based on analysis of the changes in dopamine concentration during infusion 
in neonatal simulated ward conditions.  
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Methods 
Patient and public information 
The parent’s forum group at the NICU were informed regarding the project proposed 
and consulted for their thoughts on the outcomes of our findings. 
 
Evaluation of dopamine concentration in laboratory based neonatal simulated ward 
conditions. 
In the old SOP, infusions were administered for a maximum of 24 hours. Based on the 
changes in dopamine stability observed, a new SOP was established to minimise 
changes in dopamine concentration, where infusions were prepared in syringes at 
room temperature, rested horizontally on a sterile field for 30 minutes (except the first 
dose) prior to infusion for a maximum of 12 hours. The dopamine dose used to correct 
haemodynamic imbalance in neonates is initially 3 micrograms/kilogram/minute with a 
maximum dose of 20 micrograms/kilogram/minute28. Therefore, the dosing regimens 
prepared were 0.6 mg/ml for neonatal weights of 1 kg (median weight seen in the 
NICU), 0.24 mg/ml for 400 g and 3 mg/ml for 5 kg (range of weights observed in the 
NICU). All doses were prepared by diluting vials of 200mg/5ml dopamine 
hydrochloride (Martindale Pharmaceuticals, Essex, UK) in 50 ml syringes in either 
0.45% NaCl, 0.9 % NaCl, 10 % glucose or 5 % glucose (Baxter Healthcare Ltd, 
Norfolk, UK). Infusions were placed into an incubator (Thermo Fisher Scientific) set at 
35 °C. Concentrations were analysed 30 minutes, 1 hour and 2 hours after the start of 
the infusion and 30 minutes and 1 hour before the end of the infusion for either SOP 
using high performance liquid chromatography (method in Supplementary 
information).  
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Patient group and selection criteria  
Our tertiary neonatal unit uses BadgerNet® for daily online recording of all babies 
within neonatal services. Neonates of all gestations, weights and sexes that received 
more than one subsequent dopamine infusion during their admission into the unit and 
had their BP monitored invasively were selected in this retrospective and prospective 
study. Using BadgerNet, 13 neonates meet the selection criteria who were on the old 
SOP and 17 neonates met the criteria for the new SOP (additional details on the 
patient group in Supplementary information). In the neonatal unit, for the new SOP, 
following dilution of the dopamine by the nursing staff from the adult vial into the 50 ml 
syringe, the prepared dopamine was kept horizontally on a sterile field without being 
shaken, to avoid contamination. This was kept for 30 minutes before commencing 
administration. 
 
Data collection and statistical analysis 
MetaVision® (a clinical information system for intensive care) captures all clinical 
observations on each neonate eligible to the study. Data on the birth weight, rate of 
the dopamine infusion in micrograms/kilogram/minute, total infusion duration, other 
infusions running at the same time including other inotropes, mean arterial pressure 
(MAP) 30 minutes and 1 hour pre-infusion initiation and 30 minutes, 1 hour and 2 hours 
post-infusion initiation was collected. The neonates under the old and new SOP were 
then compared. In order to measure dopamine concentration, the peak area from 
chromatography responses were obtained from identical sampling points as the MAP. 
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Data was analysed using either a one-way or two-way ANOVA with post hoc Tukey 
tests, where significance was considered when P<0.05.  
 
Results 
Initially, the changes in dopamine concentration were measured through a laboratory 
setting simulated neonatal ward. Figure 1A&B shows changes when utilising the old 
SOP in various commonly used diluent vehicles and neonate weights. There was a 
significant change in the concentration of dopamine observed with time (p<0.05, two-
way ANOVA) and a significant change in how this dopamine concentration altered in 
different diluent vehicles (p<0.05, n=10 Figure 1A). At both -1 hour and -0.5 hour 
before changeover, the dopamine concentration was more stable in 0.45 % NaCl when 
compared to 10% and 5% glucose (p<0.05, n=10, Sidak test). When comparing the 
effect of dopamine stability on doses utilised for varying weights of neonates, there 
was a signficant increase in percentage of dopamine lost with increased weight of the 
neonate (p<0.05, n=10, Figure 2C). However, with neonatal weights ≤ 0.4 kg, there is 
no difference in the dopamine concentration during infusion changeover. 
Due to the rapid loss in stability in the first 30 minutes followed by gradual loss in 
stability over 24 hours, the new SOP protocol was established to counteract these 
changes. No signficant difference in the percentage of dopamine concentration lost 
from initial concentration was observed in the varying diluent vehicles (Figure 1C, 
n=10) or weight of the neonate (Figure 1D, n=10).  
When comparing the percentage loss in the concentration of dopamine measured from 
the laboratory setting simulated neonatal ward, in all diluent vehicles there was a 
significant difference between the two SOPs over the time sampled (p<0.05, Figure 
  9 
 
2). In all cases there was a signficant increase in the percentage of dopamine lost at -
1 hour and -0.5 hour before changeover in the old SOP when compared to the new 
SOP (p<0.05, Figure 2).  
Figure 3A shows representative clinical traces spanning a 12-hour period from 3 
neonates who received dopamine infusions for 24 hours. Clear presence of rapid BP 
fluctuations was observed post infusion changeover. Figure 3B shows representative 
clinical traces over a 12-hour period from 3 neonates where dopamine infusions were 
administered for 12 hours after being prepared 30 minutes prior to infusion. No clear 
presence of rapid fluctuations was observed post infusion changeover.  
Evaluation of the changes in clinical MAP response, during changeover using the old 
and new SOP, are shown in Figure 4. There was a signficant increase in the MAP 
observed at 0.5 and 1 hour when compared to -0.5 and -1 hour in the old SOP (p<0.05, 
n=13 Figure 4A). No signficant differences in the MAP were observed during 
changeover in the new SOP (Figure 4A, n=17). When comparing the changes in MAP 
between the old and new SOP, there was a significant difference between the two 
SOPs over the time sampled (p<0.05, 2-way ANOVA, Figure 4A). There was a 
signficant reduction in the MAP at -1 hour and -0.5 hour before infusion changeover in 
the old SOP when compared to the new SOP (p<0.05, Figure 4A). 
The number of times the dose was titrated up during an infusion was compared, where 
a longer time was required for the first titrated dose (p<0.001, t-test, Figure 4B) and 
there was a decrease in the number of times the dose was titrated in the new SOP 
when compared to the old SOP (p<0.001, t-test, Figure 4C).  
Figure 5A demonstrates the observed changes in the MAP and dopamine 
concentration (for a 1 kg neonate, prepared in 5 % glucose diluent vehicle) during the 
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infusion changeover using the old SOP. Figure 5B demonstrates the observed 
changes on the MAP and dopamine concentration (for a 1kg neonate, prepared in 5 
% glucose diluent vehicle) during the infusion changeover in the new SOP. The green 
dashed line indicates when a drug concentration would be classed as unsuitable 
based on British Pharmacopia guidelines, in which dopamine concentration drop 
below this mark in the old SOP after 14 hours, whilst the response never drops below 
this point on the new SOP. 
 
Discussion 
Our study shows that by preparing dopamine 30 minutes prior to infusion and limiting 
the infusion duration to 12 hours, rapid fluctuations observed during infusion 
changeover in a 24-hour administration cycle are minimised. This new SOP is suitable 
for robust delivery of dopamine to neonates of all weights that may be treated for 
hypotension and for any dilution vehicle that dopamine is regularly prepared in for 
infusion.  
This study supports previous observational studies that have identified rapid 
fluctuations in the MAP during infusion changeover 5 9-11 29. Although many approaches 
to understand the effect observed at changeover have been taken, namely in 
evaluation and altering the practice of infusion changeover, these have yielded little 
improvement 14 18 19. The concentration of dopamine during infusion has seldom been 
investigated as a cause and this study showcases the observed changes in dopamine 
concentration during infusion in a laboratory simulated environment that replicates an 
infusion administered to a neonate within an incubator in an intensive care unit. To 
date only our previous study has shown that in a clinical environment dopamine 
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stability varies 20, and this investigation adds further information covering a range of 
dilution vehicles and neonatal weights. These findings provide significant insight into 
the impact of dose variation during infusion changeover when a 24-hour dosing cycle 
is utilised. Although many studies on dopamine stability have been conducted 21-23 26 
27, they have negated to use appropriate doses used in a clinical environment, explore 
the influence of dilution vehicle and clinical environment conditions of delivery. Our 
study indicates these parameters play a key role in reducing the stability of dopamine 
gradually over 24 hours, which leads to a significant variation during changeover 
resulting in rapid fluctuations in MAP.  
Based on these observations, the guidelines by the British Pharmacopeia guidelines 
for medicines production indicate that any product that deviates > ±7.5% from the drug 
dose would be classed as unsuitable 30 and therefore based on Figure 3, 12 hours 
was defined as the safe timescale for dopamine infusions for the new SOP as the > ± 
7.5% is breached at 14 hours as seen in Figure 2D. Additionally, most of the dopamine 
degradation was observed in the first 2 hours, and therefore it was logical to prepare 
the infusion 30-minutes prior infusion. The resultant changes assured that at no point 
was the dopamine concentration in the new SOP outside the British Pharmacopeia 
guidelines. Such changes to the new SOP also resulted in a reduction in the number 
of times the dose was titrated prior to changeover and the time taken to the first time 
the dose was titrated following changeover. 
Despite great efforts being made to simulate neonatal ward conditions as accurately 
as possible in a laboratory setting, there are a few experimental design limitations 
which can affect the interpretation of the data. These are highlighted in our previous 
publication and include the nature of the incubator utilised, which does not allow for 
maximal light, as utilised on the neonatal ward, therefore underestimating the degree 
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of degradation 20. Another important consideration is that our study is a very simple 
clinical model that does not fully mimic drug delivery of inotropes, as often they are co-
administered with other compounds, formulations, or parenteral nutrition. Additionally, 
other factors such as the type of infusion tubing and materials may also influence the 
degree of stability. 
Within our study we simulated the change in dopamine concentration as it was not 
possible to sample the infusion concentration at the varying timepoints within the 
clinical environment and match this directly with the change in MAP with the neonate. 
This type of matched observation would be of signficant advantage in understanding 
the context of dopamine concentration difference needed for a rapid fluctuation to be 
observed. Additionally, we have not fully explored the causes of dopamine’s instability, 
however we have learnt through previous studies that light is not a major cause of this 
degradation 20. Therefore, based on other studies and explored mechanisms, other 
variables such as oxygen and heat exposure may explain this degradation 21 22.  
On surveying the hypotension guidelines from numerous NICU department within the 
UK (supplementary table 1), we obtained responses from one-third of NICUs. The data 
shows all these NICU currently administered immediately in a method that reflects the 
old SOP and therefore adoption of the new SOP can have significant impact in 
reducing the risk associated with rapid fluctuations during dopamine changeover. 
However, changing dopamine infusions every 12 hours can offer a signficant change 
to practice, and requires the sterility of the infusion line to be broken twice as often.  
This proposal only focused on understanding the changes in dopamine infusions, 
however these represent only a small element of the hypotensive therapeutics 
provided and therefore further studies are needed to understand whether other 
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inotropes are stable in neonatal ward conditions when either administered individually 
or in combination. Additionally, there is a host of varying conditions in which neonates 
are cared for within an intensive care unit. Our studies have focused solely on the 
stability of dopamine for neonates nursed within incubators, however we have not 
explored if similar effects occur when using an open cot, radiant warmer or cooling 
mattress. Finally, future studies need to account for all the variations in neonatal 
intensive care conditions in which phototherapy and humidity is also influenced. Both 
parameters have been shown in other studies to influence the stability of inotropes 22 
26 and therefore this would provide key insight on whether the new SOP can overcome 
rapid fluctuations in the MAP during changeover in any given environmental condition 
used.  
 
Conclusions 
Our studies highlight that a commonly used SOP for delivery of dopamine in 
hypotensive care of neonates in intensive care units is subjective to rapid fluctuations 
in the MAP following changeover of dopamine infusions. Using a simulated 
environment, these alterations in the MAP correlated with a loss in the dopamine 
concentration as a result of degradation over 24 hours. By adopting a new SOP where 
dopamine infusions were prepared 30 minutes prior to administration and changed 
every 12 hours, both a reduction in rapid fluctuations in MAP and loss in the dopamine 
concentration due to degradation were minimised. Our new SOP has major 
implications to remove unwanted risk to neonates and should be implemented by 
clinical staff who are currently changing infusions of dopamine every 24 hours. 
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List of figures 
FIGURE 1. Changes in dopamine concentrations in a simulated neonatal ward 
laboratory setting. (A) shows the percentage of dopamine loss relative to changeover 
time, when prepared in varying dilution vehicles in the old SOP. (B) shows percentage 
of dopamine loss relative to change over time, when prepared in varying neonate 
weights in the old SOP. (C) shows the percentage of dopamine loss relative to change 
over time, when prepared in varying dilution vehicles in the new SOP. (D) shows 
percentage of dopamine loss relative to change over time, when prepared in varying 
neonate weights in the new SOP. Data shown as mean ± 95 % C.I., where *P<0.05. 
 
FIGURE 2. Difference between the new and old SOP in percent of dopamine 
concentration loss from changeover when prepared in (A) 10 % glucose, (B) 5 % 
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glucose, (C) 0.9 % sodium chloride and (D) 0.45 % sodium chloride in the laboratory 
setting simulated neonatal ward. Data shown as mean ± 95 % C.I., where *P<0.05. 
 
FIGURE 3. Representative traces of mean arterial pressures from neonates receiving 
dopamine (A) for 24 hours before infusion changeover (old SOP) or (B) which was 
prepared 30 minutes prior to infusion and ran for 12 hours before infusion changeover 
(new SOP). The green line indicates the point where infusion changeover is 
conducted, and the red line indicates the mean arterial pressure (mmHg) over time in 
hours.  
 
FIGURE 4. Difference in the MAP between the new and old SOP. (A) shows the 
difference in the mean arterial pressure. (B) shows the time following infusion 
changeover that the dose was required to be titrated and (C) shows the number of 
times the dose is titrated over 24 hours. Data shown as mean ± 95 % C.I., where 
*P<0.05 and ***P<0.001 between SOPs, †P<0.05 on the old protocol when compared 
to -0.5 and -1 hour. 
 
FIGURE 5. Shows the changes in mean arterial pressure and percentage of loss in 
dopamine concentration based over a 48 hour period in the (A) old SOP and (B) new 
SOP. The green line indicates the British Pharmacopeia guidelines for medicines 
production which is > ±7.5%. 
 
 
